Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 3/20 | 0.41 |
| ▸ | NAAA | Q02083 | 2/20 | 0.41 |
| ▸ | COMT | P21964 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | VHL | P40337 | 1/20 | 0.41 |
| ▸ | ELOC | Q15369 | 1/20 | 0.41 |
| ▸ | ELOB | Q15370 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3561302 | 0.87 | RAB9A (0.56) | RAB9AMEN1NPC1KMT2AROCK2 | |
| SCHEMBL12451876 | 0.80 | HDAC1 (0.66) | RAB9AMEN1NPC1KMT2AROCK2 | |
| SCHEMBL18364102 | 0.77 | MEN1 (0.60) | RAB9AMEN1NPC1KMT2AROCK2 | |
| SCHEMBL3558814 | 0.77 | S1PR1 (0.60) | — | |
| Biphenyl SCHEMBL27280595 | 0.76 | TSHR (0.68) | RAB9AMEN1KMT2ATSHRABCC4 | |
| SCHEMBL11274656 | 0.76 | TSHR (0.68) | RAB9AMEN1KMT2ATSHRABCC4 | |
| SCHEMBL70274 | 0.76 | TSHR (0.68) | RAB9AMEN1KMT2ATSHRABCC4 | |
| SCHEMBL3550353 | 0.76 | DRD2 (0.50) | RAB9AMEN1NPC1KMT2AHDAC1 | |
| SCHEMBL3562831 | 0.75 | MEN1 (0.58) | RAB9AMEN1NPC1KMT2AROCK2 | |
| SCHEMBL18363796 | 0.75 | MEN1 (0.58) | RAB9AMEN1NPC1KMT2AROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317649-A1 | S1P Receptor Modulating Compounds and Use Thereof | EPIX PHARMACEUTICALS, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100317649-A1 | S1P Receptor Modulating Compounds and Use Thereof | EPIX PHARMACEUTICALS, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100317649-A1 | S1P Receptor Modulating Compounds and Use Thereof | EPIX PHARMACEUTICALS, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-7790707-B2 | S1P receptor modulating compounds and use thereof | EPIX PHARMACEUTICALS INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790707-B2 | S1P receptor modulating compounds and use thereof | EPIX PHARMACEUTICALS INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790707-B2 | S1P receptor modulating compounds and use thereof | EPIX PHARMACEUTICALS INC. (US) | 2010-09-07 | — | — | US | disclosed |
| EP-2010524-A2 | S1P RECEPTOR MODULATING COMPOUNDS | Epix Delaware, Inc. (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080015177-A1 | S1P receptor modulating compounds and use thereof | AMGEN INC. | 2008-01-17 | — | — | US | disclosed |
| US-20080015177-A1 | S1P receptor modulating compounds and use thereof | AMGEN INC. | 2008-01-17 | — | — | US | disclosed |
| US-20080015177-A1 | S1P receptor modulating compounds and use thereof | AMGEN INC. | 2008-01-17 | — | — | US | disclosed |
| WO-2007109330-A2 | S1P RECEPTOR MODULATING COMPOUNDS | EPIX DELAWARE, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007109330-A2 | S1P RECEPTOR MODULATING COMPOUNDS | EPIX DELAWARE, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015177-A1 | S1P receptor modulating compounds and use thereof | S1PR1, S1PR2, S1PR5 | RAB9A 2475/4885MEN1 1502/4885NPC1 531/4885 |
| US-20100317649-A1 | S1P Receptor Modulating Compounds and Use Thereof | S1PR1, S1PR2, S1PR5 | RAB9A 2475/4885MEN1 1502/4885NPC1 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.